Investing.com - Financial Markets Worldwide
Open in App

Livzon Pharmaceutical Group Inc (000513)

Shenzhen
Symbol
Exchange
Currency
000513·Shenzhen·CNY
1513·Hong Kong·HKD
Currency in CNY
31.82
+0.29(+0.92%)
Delayed Data·
High dividend Yield
000513 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Unlock Value
Day's Range
31.2032.00
52 wk Range
25.7037.85
Key Statistics
Edit
Bid/Ask
31.80 / 31.82
Prev. Close
31.53
Open
31.56
Day's Range
31.2-32
52 wk Range
25.7-37.85
Volume
2.96M
Average Volume (3m)
11.69M
1-Year Change
-15.4828%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
000513 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Strong Buy
Analysts Sentiment
Buy
Price Target
30.09
Downside
-5.43%
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 13
Holds more cash than debt on its balance sheet
Unlock InvestingPro

Livzon Pharmaceutical Group Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

3 Buy
1 Hold
1 Sell
Ratings:
5 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 30.09
(-5.43% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
HSBC
Hold28.50-10.26%33.50MaintainSep 29, 2026
HSBC
Hold37.00+16.50%39.50MaintainApr 15, 2026

Earnings

Latest Release
Oct 23, 2026
EPS / Forecast
0.40 / 0.60
Revenue / Forecast
2.32B / 3.12B
EPS Revisions
a
a
Unlock
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 1.75
Dividend Yield
7.85%
Industry Median 1.80%
Annualized payout
2.45
Paid annually
5-Years Growth
+2.73%
Growth Streak
Unlock

000513 Income Statement

Compare 000513 to Peers and Sector

Metrics to compare
000513
Peers
Sector
Relationship
P/E Ratio
16.0x17.0x−0.2x
PEG Ratio
−0.600.120.00
Price/Book
1.9x1.6x2.6x
Price / LTM Sales
2.4x2.3x2.8x
Upside (Analyst Target)
−4.8%34.1%63.4%
Fair Value Upside
Unlock20.2%9.5%Unlock

Livzon Pharmaceutical Group Inc Company Profile

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People’s Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field; fluvoxamine maleate for the psychiatric and neurological field; and shenqi fuzheng injection and anti-viral granules for the traditional Chinese medicine field. It also produces APIs and intermediates, such as mevastatin, acarbose, teicoplanin, gentamycin sulfate, phenylalanine, vancomycin hydrochloride, daptomycin, milbemycin oxime, and ceftriaxone sodium, as well as diagnostic reagents such as diagnostic kits for IgM antibody to mycoplasma pneumonia; diagnostic kits for human immunodeficiency virus antibody; and livzon antinuclear antibody test kits. In addition, the company offers nucleic acid test kits; livzon interferon-gamma release assays test kits; influenza A/B virus antigen detection kits; and treponema pallidum antibody detection kits. Further, it provides biochemical drugs, microbiological preparations, biologic products, Chinese drug preparations and pharmaceutical raw materials, stomatitis granules, biochemical and polypeptide APIs, and antibiotic APIs, as well as diagnostic equipment. Livzon Pharmaceutical Group Inc. was incorporated in 1985 and is headquartered in Zhuhai, China.

Industry
Pharmaceuticals
Sector
Healthcare
Employees
8878
Market
China

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
80.66M9.08%2.54B
Other Institutional Investors
449.31M50.60%14.17B
Public Companies & Retail Investors
357.94M40.31%11.29B
Total
887.91M100.00%28B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Joincare Pharmaceutical Group Industry Co.,Ltd.45.23%401,572,29612,661,574
Guangzhou Begol Trading Corporation1.95%17,306,329545,669

People Also Watch

Tungsten A
40.22
000657
-1.47%
Kstar Science A
27.09
002518
-0.70%
Fenghua Adv A
31.87
000636
-2.21%
HGTECH
68.46
000988
+0.29%
Dmegc Magnetics A
16.70
002056
-0.48%

FAQ

What Is the Livzon Pharm A (000513) Stock Price Today?

The Livzon Pharm A stock price today is 31.82 CNY.

What Stock Exchange Does Livzon Pharm A Trade On?

Livzon Pharm A is listed and trades on the Shenzhen Stock Exchange.

What Is the Stock Symbol for Livzon Pharm A?

The stock symbol for Livzon Pharm A is "000513."

Does Livzon Pharm A Pay Dividends? What’s The Current Dividend Yield?

The Livzon Pharm A dividend yield is 7.9%%.

What Is the Livzon Pharm A Market Cap?

As of today, Livzon Pharm A market cap is 28.19B CNY.

What Is Livzon Pharm A's Earnings Per Share (TTM)?

The Livzon Pharm A EPS (TTM) is 1.75.

When Is the Next Livzon Pharm A Earnings Date?

Livzon Pharm A will release its next earnings report on Mar 31, 2027.

From a Technical Analysis Perspective, Is 000513 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Livzon Pharm A Stock Split?

Livzon Pharm A has split 6 times.

How Many Employees Does Livzon Pharm A Have?

Livzon Pharm A has 8878 employees.

What is the current trading status of Livzon Pharm A (000513)?

As of Nov 13, 2026, Livzon Pharm A (000513) is trading at a price of 31.82 CNY, with a previous close of 31.53 CNY. The stock has fluctuated within a day range of 31.20 CNY to 32.00 CNY, while its 52-week range spans from 25.70 CNY to 37.85 CNY.

What Is Livzon Pharm A (000513) Price Target According to Analysts?

The average 12-month price target for Livzon Pharm A is 30.09 CNY, with a high estimate of 40.03 CNY and a low estimate of 21.64 CNY. 3 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an -5.43% Downside potential.
Install Our App
Follow us
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.